Neurocrine Biosciences
NBIX
NBIX
550 hedge funds and large institutions have $12.5B invested in Neurocrine Biosciences in 2023 Q4 according to their latest regulatory filings, with 92 funds opening new positions, 205 increasing their positions, 198 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
8% more funds holding
Funds holding: 509 → 550 (+41)
2.47% more ownership
Funds ownership: 93.87% → 96.34% (+2.5%)
4% more repeat investments, than reductions
Existing positions increased: 205 | Existing positions reduced: 198
Holders
550
Holding in Top 10
12
Calls
$64.4M
Puts
$54.6M
Top Buyers
| 1 | +$360M | |
| 2 | +$138M | |
| 3 | +$67.3M | |
| 4 |
Renaissance Technologies
New York
|
+$52.5M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$48.1M |
Top Sellers
| 1 | -$156M | |
| 2 | -$82.2M | |
| 3 | -$76.3M | |
| 4 |
Bank of New York Mellon
New York
|
-$73.8M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$49.5M |